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ABSTRACT
Background: Although serum level of alpha-fetoprotein (AFP) has long been used to
complement imaging tests in the screening and diagnosis of hepatocellular carcinoma
(HCC), whether it can be used as a predictive marker of long-term risk for developing
HCC in patients with hepatitis B virus (HBV) has not been extensively evaluated and
thus remains controversial.
Methods: We retrospectively conducted a clinic-based longitudinal cohort study
including 617 Korean American patients with HBV who had been followed for up to 22
years (median follow-up time, 6.2 years) to evaluate the association between baseline
serum AFP level and the long-term risk of HCC.
Results: The median baseline AFP value of these patients was 3.8 ng/ml. Compared to
patients with lower-than-median AFP value, those with higher-than-median baseline
serum AFP had a significantly increased risk of developing HCC with an hazard ratio
(HR) of 2.73 (95% confidence interval [CI] 1.25-5.99), independent of other major HCC
risk factors. In addition, we calculated the cumulative incidence of HCC during different
years of follow-up time by baseline serum AFP, and found that the cumulative incidence
of HCC was significantly higher in HBV patients with high baseline serum AFP
compared to those with low baseline serum AFP in each of the five follow-up time
periods examined.
Conclusions: Our results indicated that AFP was a strong independent prospective
predictor of long-term HCC risk in high-risk HBV patients. More targeted prevention and
early detection of HCC may be considered for these patients.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common solid malignancy and
the third leading cause of cancer mortality worldwide, with approximately 625,000 new
cases and 600,000 deaths in each year (1-3). Hepatitis B virus (HBV) is the most
significant hepatocarcinogen which is responsible for up to 80% of HCC worldwide.
Currently there are over 400 million patients with chronic HBV infection globally which
corresponds to over 5% of the world’s population; and it is estimated that about 20% of
these infected individuals may eventually develop HCC (4, 5). The hepatocarcinogenesis
from HBV infection to HCC development has been increasingly recognized as a
multifactorial and multistep process. Observational studies have identified potential
demographic factors, viral status, clinical variables, and genetic components in HBV
patients that are associated with the risk of HCC (6-8). Although acclaimed instrumental,
many of these factors remain controversial in their roles for predicting the long-term risk
of developing HCC (6). Thus, validation of these significant risk factors for HCC would
allow further stratification of HBV patients and selection of those with the highest risk of
HCC to receive more intensive, targeted, and personalized prevention strategies.
Alpha-fetoprotein (AFP) was first identified in 1956 as a serum glycoprotein
generated by the yolk sac and the liver during fetal life (9). Generally, normal people
have a low AFP level, which may be elevated under certain diseases. Serum AFP has
long been used as a diagnostic marker for HCC, but with controversies (10). Although
still widely used in the current clinics, the use of AFP in HCC diagnosis has been
challenged in recent years due to the associated false positive and false negative findings
(11). In addition, the role of AFP as a prospective predictive marker or a surveillance
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indicator of HCC among HBV patients has not been extensively evaluated and thus
remains controversial (12-15). For example, in a prospective study including 463 patients
with liver cirrhosis, AFP was not significantly associated with HCC development within
a mean follow-up time of 3.2 years (14). In comparison, Oka et al. reported a significant
positive correlation between high baseline AFP value and increased incidence of HCC in
a cohort of 260 Japanese patients within a 5-year follow-up period (12). Consistently,
Colombo et al. reported that the risk of developing HCC in patients with persistently high
levels of AFP was more than 10 times higher than those patients with persistently low
AFP levels (15). The lack of consistency in findings from these studies are likely
accounted for by various factors, such as study design, population size and
characteristics, patient enrollment criteria, HCC etiology, and follow-up time.
Nonetheless, given the broad application of AFP measurement in the current clinics on
HCC screening, surveillance, diagnosis, and treatment, additional studies on the
predictive role of baseline AFP in long-term risk of developing HCC are warranted to
better assist clinicians to make informed decisions on HCC prevention and management.
To further assess the relationship between baseline AFP and future HCC risk, we
retrospectively conducted a clinic-based longitudinal cohort study based on a unique
population of Korean American HBV patients in the Greater Philadelphia area who have
been followed for up to 22 years. In this study, we evaluated the differences in HCC
incidence between HBV patients with high and low level of baseline AFP values. To our
knowledge, this is one of the largest clinic-based cohort studies with a long-time followup.
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MATERIALS AND METHODS
Study population
The subjects in this study were identified from an existing clinic-based patient
cohort. The patients were consecutively enrolled from those who visited the Liver
Disease Prevention Center at Thomas Jefferson University Hospital for treatment of
chronic HBV or HCV infection and liver diseases, such as cirrhosis, fibrosis, and/or
HCC. There were no restrictions on age, gender, ethnicity, and disease stage in patient
enrollment. Enrollment was initiated from 1988 and is still ongoing. As of October 2010,
the cohort included more than 2,600 patients, of which 90% were of Korean ancestry.
The cohort included patients with different etiologies and conditions, including noncancer patients with mono-infection of HBV, hepatitis C virus (HCV), or without viral
infection; and also included cancer patients with HBV-related HCC, HCV-related HCC,
or HCC without viral infection. For each patient, viral infection status was clinically
determined before enrollment. All demographic, clinical, and follow-up data for study
subjects were obtained from medical chart review and consultation with the treating
physicians. For the purpose of this study, we included all those patients who (a) were
non-cancer patients who had only HBV infection at their first clinical visits, (b) had
recorded AFP measurement within 12 months after their first clinical visit, (c) had been
followed for a minimum of 12 months, and (d) was not diagnosed with HCC within 12
months of their first clinical visit. Because the majority (>90%) of the patients who
visited the Liver Disease Prevention Center were of Korean ancestry, we further
restricted the study to Korean patients to eliminate the confounding effect from
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population stratification. This study has been reviewed and approved by the Institutional
Review Board (IRB) at the Thomas Jefferson University.
Data collection
Demographic and clinical data were abstracted from patient medical records to
create a patient-level longitudinal database. Demographic variables collected included
age, gender, ethnicity, smoking status, drinking status, self-reported family history of
HBV infection, family history of cirrhosis, and family history of cancer. Clinical
variables were collected for the first clinical visit with a recorded AFP value, including
the presence of liver cirrhosis, serum AFP, alkaline phosphatase (ALP), Alanine
Aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase
(GGT), HBV DNA load, count of white blood cell (WBC) and platelets, prothrombin
time, total protein, albumin, total bilirubin, direct bilirubin, ferritin, blood urine nitrogen
(BUN), triglyceride, low-density lipid protein (LDL), and creatinine, etc. Missing data in
these variables were noticed due to the retrospective nature of the chart review. The rate
of missing data for these variables in the initial patients’ visits ranged from 0.91% (AST)
to 39.9% (LDL). Liver cirrhosis and HCC status were determined by the combined use of
clinical diagnosis and imaging studies (ultrasound, computed tomography, or magnetic
resonance imaging) (16). Treatment data including antiviral nucleoside and nucleotide
analogs and interferons were also obtained. More than 95% of these patients received
nucleoside/nucleotide analog-based antiviral treatments. Less than 5% of patients
received interferon-based or combined treatments. For those patients who developed
HCC during follow-up, treatments usually included transarterial
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embolization/chemoembolization (TACE) radiofrequency ablation (RFA), cryoablation,
chemotherapy, and/or surgery.
Statistical Analysis
Statistical analyses were performed using the SAS software version 9.2 (SAS
Institute, Cary, NC). Continuous variables were expressed as means with standard
deviation (SD), and were compared using the student’s t test or ANOVA as appropriate.
Categorical variables were compared using the chi-square test or Fisher’s exact test,
where appropriate. The primary outcome of this study was the diagnosis of HCC. Time to
the HCC diagnosis was defined as the time from the date of first visit to the date of HCC
diagnosis, or the date of last follow-up if the patient was still alive without HCC
diagnosis at the time of this analysis. Patients free of HCC at their death or at the last
follow-up date were censored for the analysis. Incidence rates of HCC were calculated by
dividing the number of incident HCC cases by the total number of person-years of
follow-up. Cumulative incidence of HCC by follow-up year was derived using the
Nelson-Aalen method (17). Kaplan-Meier analysis was used to compare the cumulative
risk for developing HCC in patients with different levels of serum AFP. The log rank test
was used to determine the statistical significance of associations. The baseline AFP value
was treated as continuous predictor variable and grouped based on the median and tertile
distribution in all patients included in the analyses. Cox proportional hazards model was
performed to determine the association between the independent variables and the risk of
developing HCC. The risk of HCC was estimated using hazard ratio (HR) and 95%
confidence interval (CI) after adjustment for age, gender, smoking, drinking, cirrhosis,
family history of HBV, family history of cirrhosis, and family history of cancer, where
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appropriate. All statistical tests in this study were two-sided, and P<0.05 was considered
statistically significant.

RESULTS
Population Characteristics
From our database of patients enrolled from 1988 to 2010, we identified a total of
617 cancer-free Korean HBV patients who met the criteria described in the study
population in Materials and Method. Patients who developed HCC within 12 months of
their first clinical visits were excluded from the analyses. The basic demographic
characteristics of the 617 patients are listed in Table 1. The median (SD) age of all
patients was 42.1 (11.1) years. The majority of patients were males (67.6%), never
smokers (66.8%), and never drinkers (60.9%). Approximately 36.8% of the patients had
cirrhosis at the time of enrollment. There were an equal number of patients with and
without a family history of HBV infection (49.4% vs. 50.6%, respectively). The majority
of patients did not have a family history of cirrhosis (81.2%) or family history of cancer
(66.0%). The median level of baseline AFP (first measured within 12 months of first
clinic visit) of these patients was 3.8 ng/ml (Table 1).
Incidence rate and risk factors associated with the development of HCC
There were a total of 3,785 person-years of follow-up in the 617 study subjects,
with the average (SD) follow-up time period of 6.2 (4.7) years (range: 1.0-22.2 years).
During follow-up, a total of 61 HBV patients developed HCC after 12 months. We
analyzed the association of major demographic variables and baseline serum AFP value
with the risk of developing HCC using multivariate Cox proportional hazard model
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(Table 2). We found that male patients, ever smokers, and ever drinkers exhibited an
increased but non-significant risk of HCC development with an HR of 1.90 (95% CI
0.84-4.30), 1.65 (0.81-3.34), and 1.10 (0.56-2.16), respectively. Compared to patients
≤39 years old, patients who were 40-49 years old, 50-59 years old, and over 60 years old
showed an increased risk for developing HCC, with an HR (95%CI) of 1.45 (0.71-2.96),
6.28 (3.12-12.63), and 2.11 (0.85-11.40), respectively. As expected, patients with
cirrhosis had a statistically significantly increased risk of developing HCC (HR=8.02,
95% CI 3.38-19.05). Furthermore, patients who reported a family history of cirrhosis also
had a significantly increased risk of HCC with an HR (95% CI) of 3.20 (1.09-9.43).
However, no significant associations were observed between HCC risk and self-reported
family history of HBV infection (HR 0.94, 95% CI 0.52-1.69) and family history of
cancer (HR 1.13, 95% CI 0.65-1.99). There were 300 patients with a baseline AFP level
that was lower than the median value. In this group, 15 (5.0%) patients developed HCC
in an average of 7.9 years. In comparison, 46 of 317 (14.5%) patients with an AFP level
higher than the median value developed HCC in an average of 4.6 years (chi square test <
0.0001, data not shown). Multivariate Cox proportional hazard analysis indicated that
compared to patients with a lower-than-median serum AFP, those with a higher-thanmedian serum AFP value had a 2.73-fold (95% CI 1.25-5.99) increase in the risk for
developing HCC (Table 2). The incidence rates of HCC per 100,000 person-years by
baseline serum AFP level increased from 801 per 100,000 person-years for the low AFP
group to 2405 per 100,000 person-years for the high AFP group (Table 2). Moreover, a
significant difference in AFP levels was identified between HBV patients who developed
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and who did not develop HCC during follow up (P value for t test, 0.008, data not
shown).
Cumulative incidence of HCC by serum AFP level during complete follow-up
The cumulative incidence of HCC during the complete follow-up period (19882010) is shown in Figure 1. An increasing trend of cumulative HCC incidence over the
follow-up period was noted, with significantly higher cumulative incidence observed in
HBV patients with higher-than-median baseline serum AFP level compared to those
HBV patients with lower-than-median AFP levels (log-rank P<0.0001, Figure 1A). Very
similar results were obtained when the tertile distribution of baseline serum AFP value
was used to separate patients, indicating that the association between elevated baseline
AFP and increased risk of HCC was dose-dependent (Figure 1B). Because the population
in this analysis included HBV patients whose AFP level was measured within 12 months
of the first clinical visit and who had a minimum of 12 months follow-up period, there
was a possibility that some patients with high AFP value actually already had cancer but
were not diagnosed at the time of AFP measurement. The inclusion of these patients
might confound our results, because the elevated AFP value in these patients was more
like a marker of cancer detection than a predictive marker of long-term cancer risk. To
address this potential cofounder, we calculated the average time from first clinic visit to
AFP measurement as well as the average time from first clinic visit to HCC diagnosis.
We found that for 419 of the 617, the AFP measurement was conducted at the same date
of their first clinic visit. The average time of AFP measurement from the first clinic visit
was 1.3 months whereas the average time of HCC diagnosis from the first clinic visit was
5.1 years. Moreover, we further restricted the patient cohort to include only those patients
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who had the baseline serum AFP measurement done within 6 months of first clinical visit
as well as had been followed up for a minimum of 36 months and excluded those patients
who developed HCC within 12 months. This approach yielded a total of 363 non-cancer
HBV patients, among which 37 patients developed HCC after 36 months of follow-up
(data not shown). We then evaluated the cumulative incidence of HCC within this patient
cohort. Very similar results to that of the previous cohort were attained (Figure 2). That
is, the cumulative incidence of HCC was again significantly higher in those patients with
a higher-than-median AFP value, compared to those with a lower-than-median AFP value
(Figure 2A). Furthermore, we found that this effect was also in a significant doseresponse manner when the tertile, instead of median, distribution of baseline AFP was
used to group subjects (Figure 2B).
Cumulative incidence of HCC by serum AFP level at different years of follow-up
Finally, we conducted analyses to calculate the cumulative incidence of HCC
during different years of follow-up time by serum AFP level using the Nelson-Aalen
method (Table 3). We found that the cumulative incidence of HCC was significantly
higher in patients with higher baseline serum AFP than those with lower AFP value, in
each of the follow-up time periods examined. In patients with lower-than-median
baseline AFP value, the cumulative incidence of HCC was 2.4, 3.9, 5.2, 10.0, and 17.9 at
the end of 3, 6, 9, 12, and more than 18 years of follow-up, respectively. In comparison,
HCC incidence was 6.6, 10.9, 15.5, 27.8, and 40.8, respectively, in patients with higherthan-median baseline AFP values (Table 3, upper panel). Very similar results were
observed when the analysis was conducted within those 363 patients whose baseline AFP
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was measured within 6 months of first clinical visit and had been followed for more than
36 months (Table 3, lower panel).

DISCUSSION
Despite the wide application of serum AFP level in complementing other
imaging-based approaches in HCC diagnosis, there is uncertainty about whether baseline
level of AFP can predict the long-term risk of developing HCC in HBV patients (10, 12,
14). Through a retrospective analysis of a clinic-based well-characterized and
homogeneous HBV patient cohort that have been followed for up to 22 years, we found
that baseline serum AFP level was a strong indicator of the development of HCC,
independent of other demographic risk factors including age, gender, smoking, drinking,
cirrhosis, family history of HBV, family history of cirrhosis, and family history of cancer.
With a median follow-up time of 6.2 years, the HBV patients who had high baseline
serum AFP value exhibited a 2.73-fold increase in HCC risk compared to patients with
low AFP value. In addition, the cumulative incidence of HCC at the end of 18 years
follow-up was significantly higher in patients with high baseline AFP (40.8%) than those
with low baseline AFP (17.9%).
Compared to prospectively designed population-based or clinic-based studies, a
potential caveat for retrospective analysis of clinic-based cohort was patient selection
bias (18). However, when we compared the major demographic characteristics between
the 617 HBV patients included in this study to the rest of HBV patients in our cohort that
were not included in this study due to lack of measurement of baseline AFP value and/or
short follow-up time, we did not identify any significant differences (P value ranged from
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0.21 to 0.89, data not shown), indicating the chance was low for bias in patient selection
in our study. In addition, the risk association of other demographic variables calculated
by multivariate analyses was consistent with the findings from previous reports in other
Asian populations. For example, compared to patients less than 40 years old, patients
who were between 40 to 49 and 50-59 had a 1.45-fold and 6.28-fold increase in HCC
risk, respectively, consistent with the previous reports that older patients were more likely
to develop HCC in HBV patients (17, 19). However, the risk was 2.11 (95% CI 0.8511.40) in patients with an age of more than 60 years in our study, which was probably
due to the small number (N=3) of HCC patients in this age group that led to an unstable
estimate. Moreover, we found that HBV patients in our population who had liver
cirrhosis had a more than 8-fold increase in the risk of developing HCC, which was also
consistent with many previous reports on the significant positive correlation between
cirrhosis and HCC in previous studies. For example, Chen et al. reported that cirrhosis
was associated with a 21.8-fold increased HCC risk in a population-based HBV patient
cohort (19). The difference in the magnitude of increase in HCC risk between our study
(8.02) and the study from Chen et al. (21.8) could be due to the differences in patient
ethnicity, sample size, and clinic and population-based studies. Further, consistently we
found in our study that the family history of liver cirrhosis was also an independent
predictor of HCC development (Table 2). Other previously reported significant risk
factors such as male gender, ever smokers, and ever drinkers were also found in our study
to be associated with increased HCC risk. However, these associations did not reach
statistical significance. These discrepancies could be due to the nature of clinic-based
study in which most patients have higher disease severity than those patients in the
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general HBV population. The severity of HBV infection and relevant induced condition
could overshadow the effects of other demographic risk factors on HCC development. In
consistency with this notion, the lack of significant association between several major
demographic and clinical risk factors and the risk of developing HCC was also noted in
other independent clinic-based studies (13, 14, 20, 21).
The major strength of our study is the unique and highly homogenous HBV
patient population that has been completely collected in a single institute. In addition, in
comparison to many previous studies that did not differentiate HCC cases with different
etiologies, our study was focused on HCC risk in patients infected with HBV only. All
subjects were of Korean ethnicity to eliminate the confounding effects of population
stratification. In addition, the majority of the patients in our study were infected with
HBV at birth or childhood, making our population an ideal resource to study the longterm outcome of HBV infection at the population level. Our study also has limitations.
First, due to the nature of clinic-based research, the findings from this study might not be
generalized to the general population with HBV infection. Instead, the conclusion of our
study might be more applicable to high-risk HBV patients who visit clinics and seek
medical advice and/or treatment. Moreover, different AFP levels have been reported in
different ethnic groups. For example, it has been reported that in the general male
population, AFP levels were higher in Africans than in Asians (22). O’Brien et al. found
that normal Asian and African American women exhibited a higher AFP level than
Hispanic and White American women (23). Consistently, Lok et al. reported a higher
AFP level in African Americans than Caucasians (24). Since our study is restricted to
Korean HBV patients, whether the finding can be generalized to other ethnic groups
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remains a task of further evaluation. Second, all the data used in this study were obtained
from medical chart review instead of in-person interview, although we had strict criteria
for quality control of chart review as well as frequent validation with treating physicians.
Third, we also had missing values for some major clinical variables such as the status of
HBe Ag and anti-HBe, viral DNA load, levels of ALT and AST, etc. These variables
were not included in our multivariate adjustment and thus might confound our results.
However, when we used the first available measurement of these variables within 12
months of first patient clinical visit, the rate of missing data was significantly reduced yet
the inclusion of these variables in the adjustment of multivariate analyses did not
significantly changed our results (high vs. low AFP, HR=2.37, 95% CI 1.19-3.87, data
not shown). Fourth, although we observed an increased HCC risk associated with
drinking status, a commonly recognized HCC risk factor, the association did not reach
statistical significance (Table 2). This might be due to the nature of our clinic-based
cohort in which the severity of HBV patients has overshadowed the causal relationship of
drinking. It is also possible that the current categorization of never and ever drinkers is
not sufficient to accurately reflect the intensity of drinking. This issue may not be able to
be addressed using our current patient population and thus, warrants further
investigations, especially in a prospective setting. Finally, the cut-off of AFP used in this
study was determined using the median baseline value among all patients (3.8 ng/ml).
Thus, it remains to be determined whether this cut-off is applicable to different patients in
other clinical settings. A cut-off value ranged from 5 to 20 ng/ml has been reported in
other clinic-based studies as having good discriminative capability (12, 14, 24, 25). Using
a cut-off of 20 ng/ml in our study resulted in a small number of patients whose AFP was
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higher than the cut-off, which in turn led to an unstable estimate. However, a cut-off of
both 5 ng/ml and 10 ng/ml significantly differentiated HBV patients with different risks
of developing HCC in our study (log rank P<0.001 in both analyses). Nonetheless, future
larger studies are still warranted to further determine the optimum clinically applicable
AFP value in clinic-based HBV patients. Taken together, these caveats limit the clinical
applicability of the findings in our study. Prospective studies in independent populations
are warranted to further validate our findings.
In summary, we retrospectively conducted a clinic-based longitudinal cohort
study to determine the predictive role of baseline AFP value in the prediction of longterm risk of developing HCC in HBV patients. Our conclusion was that elevated serum
AFP was significantly associated with increased risk of HCC in HBV patients who seek
medical advice/treatment. The effect of high AFP on increased risk of HCC might last for
many years after the AFP measurement. Although it still remains a topic of further debate
as to whether AFP should be an integral component for HCC surveillance in the general
HBV patient population, our study indicated that high levels of serum AFP were
associated with higher risk of developing HCC in non-cancer HBV patients. Thus, more
targeted prevention and early detection of HCC may be considered for these patients.
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FIGURE LEGENDS
Fig. 1. Cumulative incidence of HCC by (A) median and (B) tertile distribution of
baseline AFP level, conducted within patients with baseline AFP measured within 12
months of first clinical visit and a minimum of 12 months’ follow-up.

Fig. 2. Cumulative incidence of HCC by (A) median and (B) tertile distribution of
baseline AFP level, conducted within patients with baseline AFP measured within 6
months of first clinical visit and a minimum of 36 months’ of follow-up.
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Table 1. Baseline characteristics of the HBV patients included in this study
Variables
Age (Mean  SD *)
Gender

Number (%) of patients (N=617)
42.2  11.1
Male
Female

417 (67.6)
200 (32.4)

Never
Ever

412 (66.8)
205 (33.2)

Never
Ever

376 (60.9)
241 (39.1)

No
Yes
Family history of HBV infection
No
Yes
Family history of cirrhosis
No
Yes
Family history of cancer
No
Yes
AFP
 median
> median
* SD, standard deviation

390 (63.2)
227 (36.8)

Smoking status

Drinking status

Cirrhosis

305 (49.4)
312 (50.6)
501 (81.2)
116 (18.8)
407 (66.0)
210 (34.6)
300 (48.6)
317 (51.4)
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Table 2. The associations of demographic variables and serum AFP value with the
risk of developing HCC in HBV patients.

Variables

Number
(%) of
patients
(N=617)

Personyears of
follow-up

Number
(%) of
HCC
cases
(N=61)

Incidence
rate per
100,000
person-years

HR (95% CI) *

P value

Age (Year)
≤39 233(40.88)
1651
8
485
Reference
40-49 194(34.04)
1179
17
1442
1.45 (0.71-2.96)
0.30
50-59 108(18.95)
531
26
4896
6.28 (3.12-12.63) <0.0001
≥60 35(6.14)
148
3
2027
2.11 (0.85-11.40) 0.09
Sex
Female 200(32.41)
1160
9
776
Reference
Male 417(67.59)
2625
52
1981
1.90 (0.84-4.30)
0.12
Smoking status
Never 412(66.77)
2544
29
1140
Reference
Ever 205(33.23)
1241
32
2579
1.65 (0.81-3.34)
0.17
Drinking status
No 376(60.94)
2369
30
1266
Reference
Yes 241(39.06)
1416
31
2189
1.10 (0.56-2.16)
0.78
Cirrhosis
No 390(63.21)
2315
7
302
Reference
Yes 227(36.79)
1470
54
3673
8.02 (3.38-19.05) <0.0001
Family history of HBV
No 305(49.31)
1894
31
1637
Reference
Yes 312(50.57)
1891
30
1586
0.94 (0.52-1.69)
0.83
Family history of cirrhosis
No 501(81.20)
3106
45
1449
Reference
Yes 116(18.80)
679
16
2356
3.20 (1.08-9.43)
0.04
Family history of cancer
No 407(65.96)
2547
37
1453
Reference
Yes 210(34.04)
1238
24
1939
1.13 (0.65-1.99)
0.67
AFP
≤median 300(48.62)
1872
15
801
Reference
>median 317(51.38)
1913
46
2405
2.73 (1.25-5.99)
0.01
* Adjusted for age, sex, smoking status, drinking status, cirrhosis, family history of HBV, family
history of cirrhosis, family history of cancer, and AFP, where appropriate.
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Table 3. Cumulative incidence of HCC by baseline serum AFP level and different
years of follow-up in patients.
Baseline serum AFP(≤ median)
Baseline serum AFP(≥median)
Cumulative incidence
Cumulative incidence
In patients with more than 12 month’s follow-up*
2.4
6.6
3
3.9
10.9
6
5.2
15.5
9
10.0
27.8
12
17.9
40.8
≥18
In patients with more than 36 month’s follow-up**
1.7
5.1
6
3.0
10.3
9
8.0
24.1
12
16.1
37.8
≥18
* Within patients who had an AFP value within 12 months of first clinical visit and who had been
follow-up for at least 12 months.
** Within patients who had an AFP value within 6 months of first clinical visit and who had been
follow-up for at least 36 months
Years of follow-up

23

